Combination Therapy of Clinically Approved Antifungal Drugs Is Enhanced by Conjugation with Silver Nanoparticles
- 5 Downloads
Silver nanoparticles (SN) have been recently developed as a new class of antimicrobial agents against numerous pathogenic microorganisms. SN have also been used as efficient drug delivery systems and have been linked with increasing drug potency. Here, we demonstrated the enhanced antifungal efficacy of nystatin (NYT) and fluconazole (FLU) after conjugation with SN. The antifungal bioactivity of NYT- and FLU-coated SN was evaluated against Candida albicans ATCC 10231 and Aspergillus brasiliensis ATCC 16404 by the agar tube dilution method. The aim of this study was to determine and compare the antifungal efficacy of NYT and FLU with their SN and, finally, the combination of both nanoparticles as NYT-SN + FLU-SN against pathogenic fungi. The results indicated that all test samples showed a dose-dependent response against tested fungi. SN significantly enhanced the antifungal effects of NYT and FLU as compared to drugs alone. We observed a remarkable increase in the percent inhibition of both fungi (90–100%) when treated with a combination of both nanoparticles NYT-SN + FLU-SN at 200 μg/mL only. Furthermore, the morphological modifications occurred at the surface of fungal species were also analyzed by atomic force microscopy (AFM) and scanning electron microscopy (SEM). While tested against primary human cell line, all SN showed negligible cytotoxicity. Hence, these results suggest that the combination of SN with NYT and FLU may have clinical implications in the treatment of fungal infections. However, in vivo studies are needed before recommending the use of these nanoparticles safely in clinical situations.
KeywordsNystatin Fluconazole Silver nanoparticles Antifungal activity Combination therapy
The authors acknowledge the Higher Education Commission of Pakistan, and the International Center for Chemical and Biological Sciences, Karachi, Pakistan, and Sunway University, Selangor, Malaysia, for their support.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56(12):1724–1732CrossRefPubMedPubMedCentralGoogle Scholar
- Araiza J, Canseco P, Bonifaz A (2006) Otomycosis: clinical and mycological study of 97 cases. Rev Laryngol Otol Rhinol 127(4):251–254Google Scholar
- Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Leitz C, Lemming LE, Nielsen L, Olesen B (2013) Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 19(8):E343–E353CrossRefPubMedGoogle Scholar
- Malhotra S, Singh S, Rana N, Tomar S, Bhatnagar P, Gupta M, Singh SK, Singh BK, Chhillar AK, Prasad AK, Len C (2017) Chemoenzymatic synthesis, nanotization and anti-Aspergillus activity of optically enriched fluconazole analogues. Antimicrob Agents Chemother 61:e00273–17.Google Scholar
- Moazeni M, Kelidari HR, Saeedi M, Morteza-Semnani K, Nabili M, Gohar AA, Akbari J, Lotfali E, Nokhodchi A (2016) Time to overcome fluconazole resistant Candida isolates: solid lipid nanoparticles as a novel antifungal drug delivery system. Colloids Surf B: Biointerfaces 142:400–407CrossRefPubMedGoogle Scholar
- Monteiro DR, Silva S, Negri M, Gorup LF, De Camargo ER, Oliveira R, Barbosa DD, Henriques M (2012) Silver nanoparticles: influence of stabilizing agent and diameter on antifungal activity against Candida albicans and Candida glabrata biofilms. Lett Appl Microbiol 54(5):383–391CrossRefPubMedGoogle Scholar
- Monteiro DR, Silva S, Negri M, Gorup LF, De Camargo ER, Oliveira R, Barbosa DB, Henriques M (2013) Antifungal activity of silver nanoparticles in combination with nystatin and chlorhexidine digluconate against Candida albicans and Candida glabrata biofilms. Mycoses 56(6):672–680CrossRefPubMedGoogle Scholar
- Patterson TF (2007) Treatment and prevention of fungal infections. Focus on candidemia. Appl Clin Edu, New York, pp VII–VIIIGoogle Scholar